| Description | This product is a phospholipid for research use only. | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.... Read More | Creative Biolabs offers the overexpression cell line which expressing the co-inhibitory and co-stimulatory immune checkpoints of human, mouse and cynomolgus monkey origin to accelerate immunotherapy discovery and development. | Parabacteroides is a Gram-negative, anaerobic, non-spore-forming genus from the family Tannerellaceae. Currently, the genus Parabacteroides includes eight valid species with standing in nomenclature. The species Parabacteroides faecis and Parabacteroides johnsonii; faeces and Parabacteroides Parabacteroides is a Gram-negative, anaerobic, non-spore-forming genus from the family Tannerellaceae. Currently, the genus Parabacteroides includes eight valid species with standing in nomenclature. The species Parabacteroides faecis and Parabacteroides johnsonii; faeces and Parabacteroides gordonii; blood were all isolated for the first time in humans. Of all the species, Parabacteroides distasonis is the reference type strain for the genus Parabacteroides. To date, Parabacteroides distasonis has been shown to have beneficial effects on colorectal cancer. Multiple researchers have identified that levels of Parabacteroides distasonis in stool are inversely correlated to the presence of intestinal tumors. The evidence for the potential anti-inflammatory effects of Parabacteroides distasonis in colorectal cancer is further supported by the inverse correlation between Parabacteroides distasonis levels and IL-1β production in the gut, suggesting that Parabacteroides distasonis has anti-tumorigenic and anti-inflammatory potential in colorectal cancer patients. Further potential benefits of Parabacteroides distasonis have been identified, particularly in relation to obesity. In addition, several studies have suggested that Parabacteroides distasonis may play a role in various forms of autoimmunity.... Read More |